SG10201505075TA - Simultaneous, Integrated Selection And Evolution Of Antibody/Protein Performance And Expression In Production Hosts - Google Patents

Simultaneous, Integrated Selection And Evolution Of Antibody/Protein Performance And Expression In Production Hosts

Info

Publication number: SG10201505075TA
Authority: SG; Singapore
Prior art keywords: evolution; antibody; simultaneous; expression; production hosts
Prior art date: 2009-07-17

Application number

SG10201505075TA

Inventor

Jay Milton Short

Original Assignee

Bioatla Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-07-17

Filing date

2010-07-16

Publication date

2015-07-30

2010-07-16 Application filed by Bioatla Llc filed Critical Bioatla Llc

2015-07-30 Publication of SG10201505075TA publication Critical patent/SG10201505075TA/en

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B30/00—Methods of screening libraries
- C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
- C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype

Landscapes

Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
General Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
General Health & Medical Sciences (AREA)
Microbiology (AREA)
Biophysics (AREA)
Medicinal Chemistry (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Computational Biology (AREA)
Crystallography & Structural Chemistry (AREA)
Ecology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Investigating Or Analysing Biological Materials (AREA)

SG10201505075TA 2009-07-17 2010-07-16 Simultaneous, Integrated Selection And Evolution Of Antibody/Protein Performance And Expression In Production Hosts SG10201505075TA (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US27116809P	2009-07-17	2009-07-17

Publications (1)

Publication Number	Publication Date
SG10201505075TA true SG10201505075TA (en)	2015-07-30

Family

ID=43450243

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
SG10201505075TA SG10201505075TA (en)	2009-07-17	2010-07-16	Simultaneous, Integrated Selection And Evolution Of Antibody/Protein Performance And Expression In Production Hosts
SG2012003356A SG177687A1 (en)	2009-07-17	2010-07-16	Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts
SG10201700096VA SG10201700096VA (en)	2009-07-17	2010-07-16	Simultaneous, Integrated Selection And Evolution Of Antibody/Protein Performance And Expression In Production Hosts

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
SG2012003356A SG177687A1 (en)	2009-07-17	2010-07-16	Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts
SG10201700096VA SG10201700096VA (en)	2009-07-17	2010-07-16	Simultaneous, Integrated Selection And Evolution Of Antibody/Protein Performance And Expression In Production Hosts

Country Status (19)

Country	Link
US (5)	US8859467B2 (en)
EP (6)	EP2454376B1 (en)
JP (3)	JP6193570B2 (en)
KR (5)	KR20190017070A (en)
CN (2)	CN102625848A (en)
AU (5)	AU2010273974B2 (en)
BR (2)	BR122015012748A2 (en)
CA (2)	CA3034484A1 (en)
DK (5)	DK2907873T3 (en)
ES (3)	ES2581318T3 (en)
HK (1)	HK1210623A1 (en)
HU (1)	HUE029328T2 (en)
IN (1)	IN2012DN00737A (en)
MX (2)	MX2012000803A (en)
MY (2)	MY173037A (en)
PL (2)	PL3042957T3 (en)
PT (1)	PT3042957T (en)
SG (3)	SG10201505075TA (en)
WO (1)	WO2011009058A2 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2454376B1 (en) *	2009-07-17	2015-12-02	Bioatla, LLC	Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts
WO2011109726A2 (en) *	2010-03-05	2011-09-09	Bioatla Llc	Homologous multi-specific antibodies
AU2015242961B2 (en) *	2010-07-16	2017-03-02	Bioatla, Llc	Novel methods of protein evolution
ES2741175T3 (en) *	2010-07-16	2020-02-10	Bioatla Llc	New methods of protein evolution
WO2012033953A1 (en)	2010-09-08	2012-03-15	Halozyme, Inc.	Methods for assessing and identifying or evolving conditionally active therapeutic proteins
WO2013067322A1 (en) *	2011-11-03	2013-05-10	Stc Biologics, Inc.	Method for determination of pharmacological properties of recombinant proteins
WO2014179363A1 (en)	2013-04-29	2014-11-06	Adimab, Llc	Polyspecificity reagents, methods for their preparation and use
DK3447493T3 (en) *	2014-01-07	2020-08-17	Bioatla Llc	PROTEIN-ORATED ORTHOLOGISTS
GB201407852D0 (en)	2014-05-02	2014-06-18	Iontas Ltd	Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules
KR102246800B1 (en) *	2014-05-13	2021-04-30	바이오아트라, 인코퍼레이티드	Conditionally active biological proteins
US20180180626A1 (en) *	2014-07-01	2018-06-28	Stc Biologics, Inc.	A method for development of recombinant proteins with fingerprint like similarity to the reference product
DK3186284T3 (en)	2014-08-28	2022-05-09	Bioatla Inc	CONDITIONALLY ACTIVE CHIMERIC ANTIGEN RECEPTORS FOR MODIFIED T-CELLS
CN106795548A (en)	2014-09-03	2017-05-31	生物蛋白有限公司	Found and Production conditions active biological protein in identical eukaryotic produces host
AU2016222830B2 (en)	2015-02-24	2021-02-25	Bioatla Llc	Conditionally active biological proteins
US10072075B2 (en) *	2015-09-23	2018-09-11	Genentech, Inc.	Optimized variants of anti-VEGF antibodies and methods of treatment thereof by reducing or inhibiting angiogenesis
CA3003399A1 (en)	2015-11-02	2017-05-11	Bioatla, Llc	Conditionally active polypeptides
IL262404B2 (en)	2016-05-13	2024-04-01	Bioatla Llc	Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof
CN111278858A (en)	2017-07-11	2020-06-12	指南针制药有限责任公司	Agonist antibodies that bind to human CD137 and uses thereof
US11718679B2 (en)	2017-10-31	2023-08-08	Compass Therapeutics Llc	CD137 antibodies and PD-1 antagonists and uses thereof
EP3713961A2 (en)	2017-11-20	2020-09-30	Compass Therapeutics LLC	Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
CN113166269A (en)	2018-11-13	2021-07-23	指南针制药有限责任公司	Multispecific binding constructs against checkpoint molecules and uses thereof
EP3966227A1 (en)	2019-05-07	2022-03-16	Voyager Therapeutics, Inc.	Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
CN111048154B (en) *	2019-12-10	2023-06-06	上海药明生物技术有限公司	Method for mapping antibody epitope
CN111462815B (en) *	2020-03-27	2023-05-02	上海祥耀生物科技有限责任公司	Construction method and device of antibody library
US11506060B1 (en) *	2021-07-15	2022-11-22	Honeywell International Inc.	Radial turbine rotor for gas turbine engine
WO2023044483A2 (en)	2021-09-20	2023-03-23	Voyager Therapeutics, Inc.	Compositions and methods for the treatment of her2 positive cancer
WO2023092004A1 (en)	2021-11-17	2023-05-25	Voyager Therapeutics, Inc.	Compositions and methods for the treatment of tau-related disorders
WO2023220695A2 (en)	2022-05-13	2023-11-16	Voyager Therapeutics, Inc.	Compositions and methods for the treatment of her2 positive cancer
WO2024030976A2 (en)	2022-08-03	2024-02-08	Voyager Therapeutics, Inc.	Compositions and methods for crossing the blood brain barrier

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL154598B (en)	1970-11-10	1977-09-15	Organon Nv	PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING.
US3817837A (en)	1971-05-14	1974-06-18	Syva Corp	Enzyme amplification assay
US3939350A (en)	1974-04-29	1976-02-17	Board Of Trustees Of The Leland Stanford Junior University	Fluorescent immunoassay employing total reflection for activation
US3996345A (en)	1974-08-12	1976-12-07	Syva Company	Fluorescence quenching with immunological pairs in immunoassays
US4196265A (en)	1977-06-15	1980-04-01	The Wistar Institute	Method of producing antibodies
US4704362A (en)	1977-11-08	1987-11-03	Genentech, Inc.	Recombinant cloning vehicle microbial polypeptide expression
US4277437A (en)	1978-04-05	1981-07-07	Syva Company	Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en)	1978-11-24	1981-06-23	Syva Company	Macromolecular environment control in specific receptor assays
US4361549A (en)	1979-04-26	1982-11-30	Ortho Pharmaceutical Corporation	Complement-fixing monoclonal antibody to human T cells, and methods of preparing same
US4366241A (en)	1980-08-07	1982-12-28	Syva Company	Concentrating zone method in heterogeneous immunoassays
US4957858A (en)	1986-04-16	1990-09-18	The Salk Instute For Biological Studies	Replicative RNA reporter systems
US4883750A (en)	1984-12-13	1989-11-28	Applied Biosystems, Inc.	Detection of specific sequences in nucleic acids
US4683195A (en)	1986-01-30	1987-07-28	Cetus Corporation	Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en)	1985-03-28	1987-07-28	Cetus Corporation	Process for amplifying nucleic acid sequences
US4800159A (en)	1986-02-07	1989-01-24	Cetus Corporation	Process for amplifying, detecting, and/or cloning nucleic acid sequences
AU622104B2 (en)	1987-03-11	1992-04-02	Sangtec Molecular Diagnostics Ab	Method of assaying of nucleic acids, a reagent combination and kit therefore
CA1323293C (en)	1987-12-11	1993-10-19	Keith C. Backman	Assay using template-dependent nucleic acid probe reorganization
WO1989006700A1 (en)	1988-01-21	1989-07-27	Genentech, Inc.	Amplification and detection of nucleic acid sequences
CA1340807C (en)	1988-02-24	1999-11-02	Lawrence T. Malek	Nucleic acid amplification process
DE68911648T2 (en)	1988-03-24	1994-06-23	Univ Iowa Res Found	CATALYTIC HYBRIDIZING SYSTEMS FOR DETECTING NUCLEIC ACID SEQUENCES BASED ON THEIR ACTIVITY AS COFACTORS IN CATALYTIC REACTIONS IN WHICH A COMPLEMENTARY, MARKED NUCLEIC ACID SAMPLE IS SPLIT.
EP0746609A4 (en)	1991-12-17	1997-12-17	Genpharm Int	Transgenic non-human animals capable of producing heterologous antibodies
DE69333243T2 (en)	1992-11-24	2004-08-19	G.D. Searle & Co., Chicago	MUTTED INTERLEUKIN-3 (IL-3) POLYPEPTIDES
US6764835B2 (en)	1995-12-07	2004-07-20	Diversa Corporation	Saturation mutageneis in directed evolution
US20030219752A1 (en) *	1995-12-07	2003-11-27	Diversa Corporation	Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof
US6238884B1 (en)	1995-12-07	2001-05-29	Diversa Corporation	End selection in directed evolution
US6171820B1 (en)	1995-12-07	2001-01-09	Diversa Corporation	Saturation mutagenesis in directed evolution
US6562594B1 (en)	1999-09-29	2003-05-13	Diversa Corporation	Saturation mutagenesis in directed evolution
US8137906B2 (en) *	1999-06-07	2012-03-20	Sloning Biotechnology Gmbh	Method for the synthesis of DNA fragments
US7033781B1 (en)	1999-09-29	2006-04-25	Diversa Corporation	Whole cell engineering by mutagenizing a substantial portion of a starting genome, combining mutations, and optionally repeating
US7163681B2 (en)	2000-08-07	2007-01-16	Centocor, Inc.	Anti-integrin antibodies, compositions, methods and uses
AU2002233340B2 (en)	2001-02-19	2008-05-22	Merck Patent Gmbh	Artificial fusion proteins with reduced immunogenicity
US7117096B2 (en)	2001-04-17	2006-10-03	Abmaxis, Inc.	Structure-based selection and affinity maturation of antibody library
JP2004532038A (en) *	2001-05-17	2004-10-21	ディヴァーサコーポレイション	Application of novel antigen-binding molecules to therapeutic, diagnostic, prophylactic, enzymatic, industrial and agricultural fields, and methods for producing and screening novel antigen-binding molecules therefor
US7647184B2 (en) *	2001-08-27	2010-01-12	Hanall Pharmaceuticals, Co. Ltd	High throughput directed evolution by rational mutagenesis
JP4791960B2 (en) *	2003-06-27	2011-10-12	バイオレン，インク．	Look-through mutagenesis
GB0520169D0 (en) *	2005-10-04	2005-11-09	Celltech R&D Ltd	Biological products
US7790655B2 (en)	2005-10-14	2010-09-07	Medimmune, Llc	Cell display of antibody libraries
EP2617827A1 (en) *	2007-03-26	2013-07-24	Celexion, LLC	Method for displaying engineered proteins on a cell surface
US7947495B2 (en)	2007-11-01	2011-05-24	Abbott Biotherapeutics Corp.	Immunoglobulin display vectors
BRPI0819092A2 (en)	2007-11-02	2014-10-14	Scripps Research Inst	DIRECTED EVOLUTION USING PROTEINS UNDERSTANDING UNNATURAL AMINO ACIDS.
US8312249B1 (en)	2008-10-10	2012-11-13	Apple Inc.	Dynamic trampoline and structured code generation in a signed code environment
EP2454376B1 (en) *	2009-07-17	2015-12-02	Bioatla, LLC	Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts
FR2957821B1 (en)	2010-03-24	2014-08-29	Inst Francais Du Petrole	NEW AREA OF CATALYST REGENERATION DIVIDED IN SECTORS FOR REGENERATIVE CATALYTIC UNITS

2010
- 2010-07-16 EP EP10800618.0A patent/EP2454376B1/en active Active
- 2010-07-16 PT PT161579651T patent/PT3042957T/en unknown
- 2010-07-16 KR KR1020197004078A patent/KR20190017070A/en not_active IP Right Cessation
- 2010-07-16 CA CA3034484A patent/CA3034484A1/en active Pending
- 2010-07-16 BR BR122015012748-3A patent/BR122015012748A2/en not_active Application Discontinuation
- 2010-07-16 HU HUE15156820A patent/HUE029328T2/en unknown
- 2010-07-16 DK DK15156820.1T patent/DK2907873T3/en active
- 2010-07-16 EP EP19210622.7A patent/EP3636759B1/en active Active
- 2010-07-16 DK DK16157965.1T patent/DK3042957T3/en active
- 2010-07-16 SG SG10201505075TA patent/SG10201505075TA/en unknown
- 2010-07-16 SG SG2012003356A patent/SG177687A1/en unknown
- 2010-07-16 MX MX2012000803A patent/MX2012000803A/en active IP Right Grant
- 2010-07-16 CN CN2010800388394A patent/CN102625848A/en active Pending
- 2010-07-16 MX MX2015005873A patent/MX347654B/en unknown
- 2010-07-16 JP JP2012520813A patent/JP6193570B2/en active Active
- 2010-07-16 CA CA2768247A patent/CA2768247C/en active Active
- 2010-07-16 ES ES15156820.1T patent/ES2581318T3/en active Active
- 2010-07-16 ES ES16157965.1T patent/ES2652340T3/en active Active
- 2010-07-16 KR KR1020127003948A patent/KR101823872B1/en active IP Right Grant
- 2010-07-16 DK DK18183032.4T patent/DK3406717T3/en active
- 2010-07-16 US US13/384,362 patent/US8859467B2/en active Active
- 2010-07-16 EP EP18183032.4A patent/EP3406717B1/en active Active
- 2010-07-16 EP EP15156820.1A patent/EP2907873B1/en active Active
- 2010-07-16 WO PCT/US2010/042302 patent/WO2011009058A2/en active Application Filing
- 2010-07-16 MY MYPI2015002586A patent/MY173037A/en unknown
- 2010-07-16 ES ES16196481T patent/ES2701931T3/en active Active
- 2010-07-16 PL PL16157965T patent/PL3042957T3/en unknown
- 2010-07-16 DK DK16196481.2T patent/DK3156485T3/en active
- 2010-07-16 PL PL15156820.1T patent/PL2907873T3/en unknown
- 2010-07-16 DK DK19210622.7T patent/DK3636759T3/en active
- 2010-07-16 KR KR1020217042385A patent/KR20220002712A/en not_active Application Discontinuation
- 2010-07-16 KR KR1020217002264A patent/KR20210013294A/en not_active Application Discontinuation
- 2010-07-16 MY MYPI2012000207A patent/MY160472A/en unknown
- 2010-07-16 EP EP16196481.2A patent/EP3156485B1/en active Active
- 2010-07-16 KR KR1020187002028A patent/KR20180010347A/en active Application Filing
- 2010-07-16 AU AU2010273974A patent/AU2010273974B2/en active Active
- 2010-07-16 CN CN201611220313.3A patent/CN107090031A/en active Pending
- 2010-07-16 BR BR112012001171-5A patent/BR112012001171B1/en active IP Right Grant
- 2010-07-16 EP EP16157965.1A patent/EP3042957B1/en active Active
- 2010-07-16 SG SG10201700096VA patent/SG10201700096VA/en unknown
2011
- 2011-11-17 US US13/298,559 patent/US10106788B2/en active Active
2012
- 2012-01-25 IN IN737DEN2012 patent/IN2012DN00737A/en unknown
2014
- 2014-09-09 US US14/481,564 patent/US10047357B2/en active Active
2015
- 2015-05-06 JP JP2015094521A patent/JP6193913B2/en active Active
- 2015-09-15 HK HK15109001.1A patent/HK1210623A1/en unknown
- 2015-10-16 AU AU2015243076A patent/AU2015243076B2/en active Active
2017
- 2017-05-15 AU AU2017203243A patent/AU2017203243B2/en active Active
- 2017-06-02 JP JP2017109593A patent/JP6681131B2/en active Active
2018
- 2018-08-31 US US16/118,673 patent/US10920216B2/en active Active
2019
- 2019-05-31 AU AU2019203813A patent/AU2019203813B2/en active Active
2021
- 2021-01-27 US US17/159,936 patent/US11976381B2/en active Active
- 2021-05-19 AU AU2021203220A patent/AU2021203220B2/en active Active

Also Published As

Publication number	Publication date
EP2454376A2 (en)	2012-05-23
AU2010273974A1 (en)	2012-02-09
US20120165201A1 (en)	2012-06-28
WO2011009058A2 (en)	2011-01-20
KR20220002712A (en)	2022-01-06
PL2907873T3 (en)	2016-10-31
AU2010273974A8 (en)	2012-02-23
PT3042957T (en)	2017-12-21
CA2768247C (en)	2019-04-09
US10106788B2 (en)	2018-10-23
HK1210623A1 (en)	2016-04-29
MX347654B (en)	2017-05-05
DK3406717T3 (en)	2020-03-16
EP3156485A1 (en)	2017-04-19
PL3042957T3 (en)	2018-03-30
AU2010273974B2 (en)	2016-01-14
KR20180010347A (en)	2018-01-30
EP2454376B1 (en)	2015-12-02
JP2017205110A (en)	2017-11-24
DK3156485T3 (en)	2019-01-07
SG177687A1 (en)	2012-02-28
IN2012DN00737A (en)	2015-06-19
EP3156485B1 (en)	2018-09-12
KR20120069664A (en)	2012-06-28
EP3636759B1 (en)	2023-10-11
AU2017203243A1 (en)	2017-06-08
JP2012533307A (en)	2012-12-27
CN102625848A (en)	2012-08-01
WO2011009058A3 (en)	2011-04-14
ES2581318T3 (en)	2016-09-05
AU2019203813A1 (en)	2019-06-20
JP6681131B2 (en)	2020-04-15
EP3406717B1 (en)	2019-12-11
JP6193913B2 (en)	2017-09-06
CN107090031A (en)	2017-08-25
EP3636759A1 (en)	2020-04-15
EP2907873B1 (en)	2016-04-06
BR112012001171A2 (en)	2017-06-13
KR101823872B1 (en)	2018-01-31
US8859467B2 (en)	2014-10-14
DK3636759T3 (en)	2023-10-23
US10920216B2 (en)	2021-02-16
AU2015243076B2 (en)	2017-02-23
MX2012000803A (en)	2012-06-01
MY160472A (en)	2017-03-15
AU2015243076A1 (en)	2015-11-05
BR122015012748A2 (en)	2020-01-07
US11976381B2 (en)	2024-05-07
AU2019203813B2 (en)	2021-03-11
CA2768247A1 (en)	2011-01-20
EP2454376A4 (en)	2013-07-10
KR20210013294A (en)	2021-02-03
EP2907873A1 (en)	2015-08-19
AU2017203243B2 (en)	2019-07-11
US20180371452A1 (en)	2018-12-27
AU2021203220A1 (en)	2021-06-10
EP3042957A1 (en)	2016-07-13
JP2015211672A (en)	2015-11-26
DK3042957T3 (en)	2018-01-02
KR20190017070A (en)	2019-02-19
MY173037A (en)	2019-12-20
SG10201700096VA (en)	2017-02-27
US20150024944A1 (en)	2015-01-22
DK2907873T3 (en)	2016-06-13
HUE029328T2 (en)	2017-02-28
US10047357B2 (en)	2018-08-14
CA3034484A1 (en)	2011-01-20
ES2701931T3 (en)	2019-02-26
BR112012001171B1 (en)	2021-09-21
EP3042957B1 (en)	2017-09-13
EP3406717A1 (en)	2018-11-28
ES2652340T3 (en)	2018-02-01
US20210207129A1 (en)	2021-07-08
AU2021203220B2 (en)	2023-05-04
US20120245036A1 (en)	2012-09-27
JP6193570B2 (en)	2017-09-13

Publication	Publication Date	Title
SG10201700096VA (en)	2017-02-27	Simultaneous, Integrated Selection And Evolution Of Antibody/Protein Performance And Expression In Production Hosts
IL250624B (en)	2018-02-28	Anti-fgfr3 antibodies and methods using same
EP3460064B8 (en)	2024-03-20	Efficient protein expression in vivo using modified rna (mod-rna)
GB0922434D0 (en)	2010-02-03	antibodies and fragments thereof
EP2433968A4 (en)	2012-12-05	Dual targeting antibody of novel form, and use thereof
IL218753A0 (en)	2012-06-28	Protein arrays and uses thereof
ZA201107486B (en)	2012-06-27	Anti-tnf-x antibodies and their uses
EP2494062A4 (en)	2013-05-29	Anti-glp-1r antibodies and their uses
EP2525813A4 (en)	2013-07-10	Anti-ilt5 antibodies and ilt5-binding antibody fragments
PT3043182T (en)	2018-04-23	Monoclonal antibodies to hemoglobin variants c, s, e and d
IL236237A (en)	2016-05-31	Tmem154 antibodies and fragments and uses thereof
HK1162538A1 (en)	2012-08-31	Novel anti-51 antibodies and uses thereof -51
IL220536A0 (en)	2012-08-30	Anti - bv8 antibodies and uses thereof
IL219136A0 (en)	2012-06-28	Anti-hepsin antibodies and methods using same
ZA201100019B (en)	2012-04-25	Variant hhip1 protein and methods and uses thereof
GB0903151D0 (en)	2009-04-08	Antibody uses and methods
IL214527A0 (en)	2011-09-27	Anti-mst1r antibodies and uses thereof
GB0906115D0 (en)	2009-05-20	Antibody and uses thereof
EP2540742A4 (en)	2014-02-12	Anti-cyr61 protein monoclonal antibodies and uses thereof
TH136549B (en)	2014-09-19	Protein drink And methods of preparation of this drink
AU2009904099A0 (en)	2009-09-17	Antibodies to C5L2 and C5aR
GB0902222D0 (en)	2009-03-25	Protein expression